IP Verse

Use Of Anti-Pd-1 Antibody In The Treatment Of Patients With Colorectal Cancer

Patent No. EP3464373 (titled "Use Of Anti-Pd-1 Antibody In The Treatment Of Patients With Colorectal Cancer") was filed by Bristol Myers Squibb on Jun 2, 2017. The application was issued on Oct 27, 2021.

Patent Summary

Treating a tumor derived from a colorectal cancer exhibiting a high degree of microsatellite instability (MSI-H) in a subject in need thereof. The treatment involves administering nivolumab at a dose of about 3 mg/kg body weight in combination with the anti-CTLA-4 antibody ipilimumab at a dose of about 1 mg/kg body weight once about every three weeks.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GREINERJul 27, 2022GREINER
LEDERER & KELLERJul 26, 2022LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBB
MAIWALD PATENTANWALTSJul 26, 2022MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH
PAJAROJul 26, 2022BIRD & BIRD
POHLMANJul 26, 2022POHLMAN
MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBJul 25, 2022MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3464373

BRISTOL MYERS SQUIBB
Application Number
EP17731359A
Filing Date
Jun 2, 2017
Status
Revoked
Aug 4, 2023
Publication Date
Oct 27, 2021
External Links
Slate, Register , Google Patents